KPC-39-mediated resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 clinical isolate,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

KPC-39-mediated resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 clinical isolate
Antimicrobial Agents and Chemotherapy ( IF 4.1 ) Pub Date : 2021-10-04 , DOI: 10.1128/aac.01160-21
Agnès B Jousset _{1,

2,

3,

4} , Saoussen Oueslati _{1,

3} , Cécile Emeraud _{1,

2,

3,

4} , Rémy A Bonnin _{1,

2,

3} , Laurent Dortet _{1,

2,

3,

4} , Bogdan I Iorga ₅ , Thierry Naas _{1,

2,

3,

4}

Affiliation

Resistance to ceftazidime–avibactam (CAZ-AVI) combination is being increasingly reported. Here, we report a CAZ-AVI resistant Klebsiella pneumoniae belonging to the high-risk ST307 clone and producing KPC-39, a single amino-acid variant of KPC-3 (A172T). ...

中文翻译：

KPC-39 介导的肺炎克雷伯菌 ST307 临床分离株对头孢他啶-阿维巴坦的耐药性

头孢他啶-阿维巴坦 (CAZ-AVI) 联合用药耐药的报道越来越多。在这里，我们报告了一种属于高风险 ST307 克隆并产生 KPC-39（KPC-3 (A172T) 的单个氨基酸变体）的耐 CAZ-AVI 肺炎克雷伯菌。...

更新日期：2021-10-06

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11